Candriam SCA’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Candriam SCA’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-167,221	Closed	-$7.09M	–	746
2023 Q4	$7.09M	Sell	167,221 -160,000	-49%	-$4.6M	0.05%	300
2023 Q3	$7.14M	Hold	327,221	–	–	0.05%	264
2023 Q2	$10.4M	Hold	327,221	–	–	0.08%	241
2023 Q1	$7.35M	Hold	327,221	–	–	0.05%	301
2022 Q4	$10.3M	Sell	327,221 -70,000	-18%	-$1.98M	0.07%	272
2022 Q3	$11.2M	Hold	397,221	–	–	0.08%	240
2022 Q2	$10.5M	Buy	397,221 +145,603	+58%	+$4.13M	0.09%	217
2022 Q1	$8.81M	Buy	251,618 +146,019	+138%	+$4.26M	0.06%	272
2021 Q4	$3.42M	Buy	+105,599	New	+$3.73M	0.02%	439

Other funds holding CERE

BCI

Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Candriam SCA's CERE Position: Q1 2024 in Review

Candriam SCA sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q1 2024, closing a stake of 167,221 shares — an estimated $7.09M sold.

Candriam SCA first reported a position in CERE in Q4 2021 and held it in 9 quarters. The position peaked at $11.2M in Q3 2022. 210 funds tracked by Wall St. Rank hold CERE as of Q1 2024.

Candriam SCA reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
Candriam SCA sold 167,221 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q1 2024, an estimated $7.09M.
Candriam SCA first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2021 and held it in 9 quarters.
Candriam SCA's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $11.2M in Q3 2022.
210 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q1 2024.

Based on Candriam SCA's 13F filing for Q1 2024, filed 6 May 2024.